Analysts See $-0.85 EPS for Mirati Therapeutics, Inc. (MRTX)

October 8, 2017 - By Dolores Ford

 Analysts See $ 0.85 EPS for Mirati Therapeutics, Inc. (MRTX)
Investors sentiment decreased to 0.68 in 2017 Q2. Its down 1.26, from 1.94 in 2017Q1. It fall, as 19 investors sold Mirati Therapeutics, Inc. shares while 15 reduced holdings. 12 funds opened positions while 11 raised stakes. 11.06 million shares or 8.92% less from 12.14 million shares in 2017Q1 were reported.
Element Capital Mgmt Lc has 0.08% invested in Mirati Therapeutics, Inc. (NASDAQ:MRTX). The United Kingdom-based Barclays Public Limited has invested 0% in Mirati Therapeutics, Inc. (NASDAQ:MRTX). Federated Pa has invested 0% in Mirati Therapeutics, Inc. (NASDAQ:MRTX). Susquehanna Grp Inc Ltd Liability Partnership stated it has 0% in Mirati Therapeutics, Inc. (NASDAQ:MRTX). 3,100 were reported by Group Inc One Trading Limited Partnership. Meeder Asset Incorporated reported 0% stake. Connor Clark Lunn Investment Mngmt stated it has 15,900 shares or 0% of all its holdings. Baker Bros Limited Partnership reported 2.27M shares. Berson & Corrado Investment Advisors Ltd has invested 0.02% in Mirati Therapeutics, Inc. (NASDAQ:MRTX). Northern Trust accumulated 0% or 44,365 shares. Bnp Paribas Arbitrage Sa reported 2 shares. Macquarie Grp Inc Ltd holds 80,000 shares. Broadfin Capital Limited Liability reported 1.1% of its portfolio in Mirati Therapeutics, Inc. (NASDAQ:MRTX). Millennium Mgmt holds 0% of its portfolio in Mirati Therapeutics, Inc. (NASDAQ:MRTX) for 217,990 shares. Alyeska Inv Grp Ltd Partnership reported 244,574 shares.

Investors wait Mirati Therapeutics, Inc. (NASDAQ:MRTX) to report on November, 2. its quarterly earnings Wall Street analysts expect $-0.85 earnings per share, up $0.12 or 12.37 % from last year’s $-0.97 same quarter earnings. Mirati Therapeutics, Inc.’s Wall Street analysts see 14.86 % negative EPS growth, taking into account the $-0.74 EPS reproted in the previous quarter, The stock decreased 2.68% or $0.4 on October 6, reaching $14.5. About 504,739 shares traded. Mirati Therapeutics, Inc. (NASDAQ:MRTX) has declined 76.51% since October 8, 2016 and is downtrending. It has underperformed by 93.21% the S&P500.

Mirati Therapeutics, Inc. (NASDAQ:MRTX) Ratings Coverage

Among 10 analysts covering Mirati Therapeutics (NASDAQ:MRTX), 7 have Buy rating, 0 Sell and 3 Hold. Therefore 70% are positive. Mirati Therapeutics had 23 analyst reports since September 17, 2015 according to SRatingsIntel. On Monday, June 6 the stock rating was downgraded by Leerink Swann to “Mkt Perform”. The stock of Mirati Therapeutics, Inc. (NASDAQ:MRTX) has “Buy” rating given on Monday, September 18 by Oppenheimer. The stock of Mirati Therapeutics, Inc. (NASDAQ:MRTX) earned “Market Perform” rating by Leerink Swann on Friday, September 15. The firm has “Hold” rating by Jefferies given on Monday, September 11. Leerink Swann maintained the shares of MRTX in report on Thursday, March 10 with “Outperform” rating. The stock of Mirati Therapeutics, Inc. (NASDAQ:MRTX) has “Buy” rating given on Monday, June 6 by Citigroup. Jefferies maintained it with “Hold” rating and $500 target in Friday, August 4 report. The firm earned “Buy” rating on Wednesday, January 13 by Citigroup. Jefferies maintained it with “Buy” rating and $29 target in Thursday, March 10 report. The stock of Mirati Therapeutics, Inc. (NASDAQ:MRTX) has “Market Outperform” rating given on Friday, May 6 by Avondale.

More important recent Mirati Therapeutics, Inc. (NASDAQ:MRTX) news were published by: Seekingalpha.com which released: “Mirati Brings Hope With Its Stellar Performance” on September 21, 2017, also Marketwatch.com published article titled: “Mirati Therapeutics’ stock soars on heavy volume after positive cancer …”, Nasdaq.com published: “Options Traders Expect Huge Moves in Mirati Therapeutics (MRTX) Stock” on September 18, 2017. More interesting news about Mirati Therapeutics, Inc. (NASDAQ:MRTX) was released by: Seekingalpha.com and their article: “Mirati Therapeutics: Double Could Be Just The Beginning” with publication date: September 18, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts

Twitter Auto Publish Powered By : XYZScripts.com